BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Subsequently, additional results were observed in a mouse model of BCR::ABL-positive CML, where arsenic acted on BCR::ABL by directly binding the RING finger domain of c-CBL to inhibit its self-ubiquitination/degradation, while imatinib inhibits the PI3K/AKT/mTOR pathway (Zhang et al. 2009; Mao et al. 2010; Liu et al. 2014).